article thumbnail

Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Medical Xpress - Cardiology

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

article thumbnail

Why Waiting Until Age 50 To Address Risk Factors For Heart Disease Is Too Late.

Dr. Paddy Barrett

When you look at the risk of having a heart attack, it is true that the older you are, the greater the odds of having a heart attack 1. While only 1-2% of those having a heart attack are less than 65 years of age, 1-2% of this very large number means a LOT of heart attacks.

article thumbnail

Can gardening ward off heart attacks?

Heart Sisters

This study looked at what gardeners already suspect: "Gardening is associated with better cardiovascular health among older adults compared to older adults who do not garden"

article thumbnail

Study finds constipation is a significant risk factor for major cardiac events

Medical Xpress - Cardiology

An international study led by Monash University researchers has found a surprising connection between constipation and an increased risk of major adverse cardiac events (MACE), including heart attacks, strokes and heart failure.

article thumbnail

Q&A: Could a new drug help prevent heart attacks and strokes?

Medical Xpress - Cardiology

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and strokessomething no existing treatment has been able to do.

article thumbnail

Proposed risk factor tool finds heart failure rates are higher among American Indian adults

Science Daily - Heart Disease

An analysis based on a proposed heart failure risk prediction tool reveals that the incidence of heart failure may be 2- to 3-fold higher among American Indian adults compared to people in other population groups.

article thumbnail

SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease

Med Page Today

(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.